Disruption of nuclear envelope integrity as a possible initiating event in tauopathies.
ASO
CP: Neuroscience
CRISPR genetic screen
LEM domain proteins
microtubule associate protein tau
neurodegeneration
nuclear envelope integrity
nuclear envelope rupture
tau aggregation
tau phosphorylation
tauopathy
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
23 08 2022
23 08 2022
Historique:
received:
08
03
2022
revised:
23
06
2022
accepted:
29
07
2022
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
27
8
2022
Statut:
ppublish
Résumé
The microtubule-associated protein tau is an abundant component of neurons of the central nervous system. In Alzheimer's disease and other neurodegenerative tauopathies, tau is found hyperphosphorylated and aggregated in neurofibrillary tangles. To obtain a better understanding of the cellular perturbations that initiate tau pathogenesis, we performed a CRISPR-Cas9 screen for genetic modifiers that enhance tau aggregation. This initial screen yielded three genes, BANF1, ANKLE2, and PPP2CA, whose inactivation promotes the accumulation of tau in a phosphorylated and insoluble form. In a complementary screen, we identified three additional genes, LEMD2, LEMD3, and CHMP7, that, when overexpressed, provide protection against tau aggregation. The proteins encoded by the identified genes are mechanistically linked and recognized for their roles in the maintenance and repair of the nuclear envelope. These results implicate the disruption of nuclear envelope integrity as a possible initiating event in tauopathies and reveal targets for therapeutic intervention.
Identifiants
pubmed: 36001963
pii: S2211-1247(22)01067-1
doi: 10.1016/j.celrep.2022.111249
pii:
doi:
Substances chimiques
CHMP7 protein, human
0
Endosomal Sorting Complexes Required for Transport
0
LEMD2 protein, human
0
Membrane Proteins
0
Nuclear Proteins
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
111249Subventions
Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of interest The authors are employees of and shareholders in Regeneron Pharmaceuticals (“Regeneron”). Regeneron has filed patent applications around the described work. The authors declare no competing interests.